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(95%CI 1.44, 48.35) for patients with the VKORC1 TT (rs9923231) genotype com-
pared with other genotypes. The mean cost of health care attributable to warfarin 
therapy was a392. The management of warfarin-related adverse events contributed to 
53% of the overall cost. The mean costs for those who experienced an adverse event 
was a884 (95%CI, 554, 1837) compared with a178 (95%CI, 164, 192) for the 179 
patients who did not. CONCLUSIONS: Our analysis is the ﬁ rst to demonstrate a 
signiﬁ cant association between VKORC1 variant genotype and hospitalization.
Although no independent effect on total cost was evident, carriers of VKORC1 TT 
were eight times more likely to be hospitalized due to adverse events.
PM3
USE OF PHARMACOGENETIC TESTING TO DETERMINE ADJUVANT
HORMONAL THERAPY CHOICE IN EARLY STAGE BREAST CANCER
PATIENTS: A VALUE OF INFORMATION ANALYSIS
Woods BS, Hawkins NS
Oxford Outcomes (UK), Oxford, UK
OBJECTIVES: To estimate the uncertainty regarding adjuvant treatment selection for 
postmenopausal women with early stage oestrogen-receptor positive breast cancer 
when pre-treatment CYP2D6 pharmacogenetic testing is considered as an option. In
addition, the expected value of partial perfect information (EVPPI) was estimated for 
different parameter sets to inform research prioritisation. METHODS: A decision 
analytic model estimated lifetime costs and quality adjusted life years (QALYs) for
four comparators: 5 years of tamoxifen; 5 years of an aromatase inhibitor (AI);
CYP2D6 test and treat wt/wt genotypes with tamoxifen and other genotypes with an 
AI; CYP2D6 test and treat wt/wt and wt/*4 genotypes with tamoxifen and *4/*4 
genotypes with an AI. No trial data for CYP2D6 contingent treatment pathways were 
identiﬁ ed. Trial data comparing tamoxifen to anastrozole was therefore synthesised 
with observational data linking CYP2D6 genotype to recurrence in patients receiving
tamoxifen. Estimates of the EVPPI were derived by attaching distributions to input
parameters and using two-level Monte Carlo simulation. EVPPI estimates were gener-
ated for parameters describing the efﬁ cacy of tamoxifen and anastrozole; parameters 
describing genotype-speciﬁ c tamoxifen efﬁ cacy; genotype prevalence; utility weights
and health state costs. RESULTS: The strategy of CYP2D6 test and treat wt/wt
patients with tamoxifen and all others with an AI maximised expected net beneﬁ t 
assuming a decision threshold of a30,000/QALY, and had an incremental cost-effec-
tiveness ratio of a14,133/QALY. However, this maximised net beneﬁ t with only 61% 
certainty. This substantial decision uncertainty led to an expected value of perfect
information estimate of a84 million. The EVPPI estimate for parameters describing 
genotype-speciﬁ c tamoxifen efﬁ cacy was a57 million. Estimates for other parameter
groups were low. CONCLUSIONS: Further CYP2D6 genotyping studies amongst
patients receiving tamoxifen should be prioritised. Expected value of sample informa-
tion analysis could be used to establish the cost-effectiveness and optimal design of 
this primary research.
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AN EXPLORATION OF THE POTENTIAL CLINICAL BENEFITS
AND RISKS OF CYP2D6 TESTING TO GUIDE TAMOXIFEN THERAPY
IN BREAST CANCER
Veenstra DL, Lin MP, Garrison LP, Burke W
University of Washington, Seattle, WA, USA
OBJECTIVES: Recent studies have reported that women receiving adjuvant tamoxifen
with CYP2D6 poor metabolizer genotype have a higher risk of breast cancer recur-
rence than women without poor metabolizer genotype. The objective of this study 
was to evaluate pharmacogenetic testing for CYP2D6 variants as an approach to help 
clinicians identify postmenopausal women that would be better candidates for alterna-
tive therapies. METHODS: We developed a decision-analytic lifetime Markov model 
consisting of 6 health states and assessed a hypothetical cohort of 64-year old women
with ER breast cancer receiving tamoxifen. We assumed women who were poor
metabolizers would be switched to anastrazole. The incidence of local regional relapse, 
metastasis, and breast cancer death were obtained from the 2005 ATAC trial. The 
hazard ratio for disease recurrence in poor vs. extensive metabolizers was derived from 
a recent study by Goetz et al. Cost, utilities and background mortality rates were 
obtained from the published literature or publicly available sources. One-way sensitiv-
ity analyses and scenario analyses were conducted to evaluate uncertainty. RESULTS:
Projected disease free survival at 5 years was 81.4% for tamoxifen and 83.3% for
anastrozole, compared to 81.0% and 83.8% in the ATAC trial. Treatment with
tamoxifen resulted in 11.95 QALYs, anastrozole 12.15 QALYs, and CYP2D6-guided 
treatment 12.19 QALYs. The testing strategy resulted in the greatest QALYs with a 
hazard ratio for recurrence in CYP2D6 variant versus wild-type patients of 1.66 or 
higher, or variant prevalence greater than 20%. CONCLUSIONS: Genetic testing for 
CYP2D6 status in postmenopausal women taking adjuvant tamoxifen may lead to 
clinically meaningful improvements in survival and quality of life. Evaluation of the 
relative impact of drug-related adverse events, validation of association studies, and
assessment in ethnically diverse populations are needed before widespread testing can 
be recommended.
PODIUM SESSION I: RESEARCH ON METHODS – Utility Methods
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ON THE ISSUE OF UTILITY MULTIPLICATION: A REVISIT
Fu AZ
Cleveland Clinic, Cleveland, OH, USA
OBJECTIVE: Several estimators exist when average utility scores are not available for
patient populations with multiple disease conditions. The multiplicative estimator is 
a widespread choice among them. This study is to empirically test the accuracy of the
multiplicative estimator and compare it with other estimators. METHODS: Using the
pooled Medical Expenditure Panel Survey (MEPS) 2001 and 2003 data, a sample of 
40,846 adults with EQ-5D preference-based index scores were categorized into 238
disease condition categories. Due to the MEPS sampling property, co-morbid pair 
categories with less than 100 individuals were excluded, which left us with 760 co-
morbid pairs in total. The study focus was the bias from the estimators to the observed 
mean scores for each co-morbid pair, with the observed scores presumed to be the 
true value. The analyses were conducted using both the raw estimators and the res-
caled (puriﬁ ed) estimators. Regressions and concordance correlation coefﬁ cients were 
also used to evaluate the agreement between the estimators and the observed scores.
RESULTS: Using the rescaled approach, the scores estimated by multiplying the 2
mean scores of the corresponding disease conditions on average had a statistically 
signiﬁ cantly larger bias (p  0.0001) from the observed ones (0.043) than simply 
picking the smaller mean of the 2 paired conditions (minimum estimator, bias  0.027). 
However, the multiplicative estimator had less bias than other estimators including 
the additive estimator (bias  0.054), the larger mean (bias  0.077), the average of 
the means (bias  0.052), mean of the condition with smaller sample (bias  0.053). 
Results produced by other analyses, including using the raw scores, all favored the 
minimum estimator than the multiplicative estimator. CONCLUSIONS: Multiplica-
tion is not a good estimate when the average utility score for patients with 2 disease
conditions is not readily available. The lower of the 2 utility scores had the least error 
among those estimators that we compared.
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ELICITING TIME TRADE-OFF AMOUNTS FOR HEALTH STATES IN
HYPOTHETICAL INDIVIDUALS OF DIFFERENT AGES USING A 
DISCRETE CHOICE EXPERIMENT
Prosser LA1, Rusinak D2, Payne K3, Shi P2, Uyeki TM4, Messonnier M4
1University of Michigan, Ann Arbor, MI, USA, 2Harvard Pilgrim Health Care and Harvard 
Medical School, Boston, MA, USA, 3University of Manchester, Manchester, UK, 4Centers for 
Disease Control and Prevention, Atlanta, GA, USA
OBJECTIVE: To measure whether public values for health vary with the age of the
affected individual. METHODS: We ﬁ elded a discrete choice experiment via the
internet in December 2007 to measure preferences for different attributes of inﬂ uenza-
related health states: length of episode (days of illness), severity of illness (workdays
lost), age of hypothetical affected individual (range: 1–85 yrs), and time-tradeoff 
amounts (1day – 2 yrs). We also collected data on socio-demographic characteristics 
and experience with inﬂ uenza illness. Respondents were 18 years and older and
matched to reﬂ ect characteristics of the general US adult population (n  1012). 
Response rate was 67%. Respondents were presented with pairs of illness proﬁ les for
a hypothetical individual and indicated the proﬁ le they preferred. Each respondent
answered 8 discrete choice questions. A full factorial design was used. Discrete choice
analysis using generalized estimating equations was used to evaluate the relative value
of different attributes in the illness proﬁ le while controlling for socio-demographic 
characteristics and inﬂ uenza experience. RESULTS: As measured by time-tradeoff 
amounts, respondents preferred shorter inﬂ uenza episodes (total length) but did not
signiﬁ cantly prefer fewer workdays lost if episode length was held constant. Respon-
dents preferred to avert uncomplicated illness in very young children (1 year old child:
odds ratio  2.35, p  0.05; 3 year old child: odds ratio  3.21, p  0.01) and older
adults (85 year old: odds ratio  2.41, p  0.05) compared to a 35 year old adult. For 
an inﬂ uenza-related hospitalization, respondents preferred to avert illness in very 
young children (1 year old child: odds ratio  2.86, p  0.01) compared to a 35 year 
old adult. CONCLUSIONS: Approaches that assume values for illnesses do not vary
with the age of a patient may bias economic analyses that use these values. If patient
age is likely to affect valuations, then age should be included as an attribute in the
valuation exercise.
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THE VALUE OF ADDED LIFE YEARS AS A FUNCTION OF AGE, 
PROGNOSIS AND QUALITY OF LIFE
van Hout BA
Pharmerit Ltd, York, North Yorkshire, UK
OBJECTIVE: Do people weigh gains in life years differently when patients differ in 
age (but not in life expectancy), life expectancy (but not in age) or QOL (but not age 
or life expectancy)? METHODS: Trade off questions wer developed searching for
indifference between giving healthy life years to patients with different ages, prognoses 
and quality of life. Data come from 46 heart failure patients, 60 healthy controls and 
180 students. For age, as well as prognosis and QOL, six comparative sets were 
developed. Each respondent answered two questions of each set and two combina-
tion-questions. Ordered logistic regression was used in combination with conditional 
linear regression for “extreme” answers. Answers are “extreme” when, for example, 
one extra life year in a young patient is preferred to 10 in an old patient or when
respondents can’t choose. RESULTS: More than 40% of the answers are “extreme”.
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Respondent prefer to give to the young and to those who are worse off, either now
(quality of life), or in the future (prognosis). Elderly individuals, more often, prefer 
not to prioritize. It is estimated that an additional life year in a 20 year old is worth 
12.8 times the value of an additional year in an 80 year old. An additional life
year given to someone with a life expectancy of ﬁ ve years is worth 2.12 times that of 
one given to someone with a life expectancy of 10 years. An additional life year in 
someone with a utility that is 0.25 lower than someone else it is worth 2.45 times 
more. CONCLUSIONS: All results indicate that people do not think that a QALY is
a QALY and that the value of life years depends on the age of the respondent, the
prognoses of the patients and the patients’ current quality of life.
UT4
SOCIAL PREFERENCES FOR EQ-5D HEALTH STATES: IS IT TIME
TO CALL “TIMEOUT” ON TTO?
Bailey HH1, Kind P2
1University of the West Indies, St. Augustine, Trinidad and Tobago, 2University of York, York, UK
The valuation of health beneﬁ t is arguably the most fundamental issue underpinning
all clinical and economic evaluation. However, there is disagreement about the choice
of method by which such valuation is established. Advice issued by HTA agencies
generally favours utility elicitation methods but there is growing support for simpler 
methods that evoke ordinal judgments. Decision-makers face difﬁ cult choices when 
reviewing evidence based on different valuation methods. OBJECTIVES: To examine 
the extent to which ordinal preferences captured through VAS ratings are preserved
by TTO utility elicitation methods. METHODS: The UK MVH study (n  3,395) 
provides the empirical basis for the EQ-5D values required in economic evaluations 
submitted to NICE. This study collected both VAS ratings and TTO utilities for 13
EQ-5D health states per respondent. These data have been re-analysed for the pur-
poses of this paper. RESULTS: Spearman’s Rank Correlation Coefﬁ cient (rho) for TTO 
and VAS valuations was computed on a within-subject basis for all respondents, yield-
ing a mean of 0.771. 45% of respondents had a Spearman’s rho of less than 0.80 
(equivalent to a mean absolute difference of 1.7 in ranking over all 13 states). Over 
85% of respondent’s TTO values differed in rank by more than 3/13 places when 
compared with VAS ratings. Respondent characteristics did not account for differences 
in rankings of TTO and VAS scores. CONCLUSIONS: This study shows that for 
almost half the MVH respondents, TTO utilities did not coincide with ordinal prefer-
ences as revealed by their VAS scores. These results challenge a number of basic
assumptions – about the transformation of ordinal values into cardinal utilities; the 
superiority of TTO over VAS methods and the extent to which TTO “accurately”
represents individual preferences at all. Ultimately they undermine the status of TTO 
as a legitimate measure of preferences in social decision-making.
PODIUM SESSION II: HEALTH CARE DECISION-MAKER’S
CASE STUDIES II
CASE4
DIABETES PHYSICIAN RECOGNITION IN A LARGE HEALTH PLAN
Kramer M1, Perez HE2, Stacy T2
1Aetna, Brunswick, MD, USA, 2Total Therapeutic Management Inc, Kennesaw, GA, USA
ORGANIZATION: Aetna Inc. is one of the nation’s leading diversiﬁ ed health
care beneﬁ ts companies, serving approximately 37.2 million people. PROBLEM OR 
ISSUE ADDRESSED: To increase the number of physicians that are NCQA Diabetes 
Physician Recognition Program (DPRP) recognized in two pilot regions. GOALS:
(1) To increase the number of high-volume Aetna contracted practitioners (PCPs) 
located in targeted geographic areas (South Florida and Southeast PA) with Diabetes
Physician Recognition Program (DPRP) recognition (2) To provide physicians
with tools to support the delivery and recognition of consistent high quality care. 
OUTCOMES ITEMS USED IN THE DECISION: Clinical efﬁ cacy/effectiveness 
IMPLEMENTATION STRATEGY: The Aetna National Quality Management Diabe-
tes Work Group met and agreed on the implementation of a three phase program to
increase the number of NCQA DPRP recognized practitioners. Aetna conducted an 
analysis of two service areas (South FL and Southeastern PA) to rank the high volume 
Aetna contracted practitioners with the most Aetna members over the age of 18 with 
a diagnosis of diabetes. The member must have been under the care of the practitioner 
in calendar year 2007. For the practitioner to qualify he must have at least 25 Aetna 
members meeting this criteria. Forty practitioners were recruited into the program 
(20 from each service area). Aetna utilized Total Therapeutic Management (TTM),
a research organization, to implement the three phase program. In phase 1, TTM
recruited the qualifying practitioners and conducted an in- ofﬁ ce chart review to
abstract data consistent with the Comprehensive Diabetes Care Healthcare Effective-
ness Data and Information Set (HEDIS) measures. TTM utilized its Diabetes Perfor-
mance and Enhancement Program (DPReP) electronic application to provide the 
practitioners with a report to see if they met the point criteria for recognition. In phase
2, TTM conducted face-to-face outreach to discuss recognition standing, patient con-
sults (ClinAdvisor), and pharmacy compliance reports. The ClinAdvisor patient con-
sults detailed clinical outcomes such as, A1C, BP, LDL goal, etc. Also during the visit
Aetna-developed tools were provided such as chart stickers, eye exam report forms,
and 3-year diabetes checklist to promote quality improvement in tracking and manag-
ing members with diabetes. TTM communicated with the practitioner during the six-
month waiting period in areas that needed improvement. In phase 3, TTM conducted 
chart reviews based on the criteria set forth by NCQA. TTM input the abstracted 
data into its electronic application to evaluate recognition status. RESULTS: In order 
to achieve diabetes recognition, practitioners must have a cumulative score of 75
points or more from ten measures related to diabetes care. Of the 40 practitioners 
that participated in the program four had the potential points necessary to meet the
recognition standing score of 75 points in the initial evaluation. After the second 
review conducted approximately six months after the ﬁ rst review, 18 practitioners 
agreed to participate in phase 3. Of the 18 practitioners participating, 17 practitioners 
met the criteria for DPRP recognition. LESSONS LEARNED: Practitioners are aware 
of the beneﬁ ts of Pay for Performance initiatives. They are also aware of the various 
recognition programs available through NCQA. Practitioners have expressed concern 
about the time or ofﬁ ce staff necessary to conduct their own chart reviews and submit
the application to become a recognized provider. If there is a process in place to 
conduct chart reviews and provide chart review-based recommendations and other
practitioner tools, there is a strong possibility that more practitioners can meet the
requirements set forth by NCQA to become a DPRP recognized provider for diabetes 
and other conditions.
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HARMACOECONOMIC APPLICATIONS IN FORMULARY MANAGEMENT: 
A CASE STUDY OF ERLOTINIB AT A MAJOR CANCER CENTER
Lal LS1, Ugwu C2, DaCosta Byﬁ eld S1, Miller LA1, Arbuckle R1
1University of Texas M.D. Anderson Cancer Center, Houston, TX, USA, 2University of 
Houston, Houston, TX, USA
ORGANIZATION: University of Texas- MD Anderson Cancer Center (M. D. Ander-
son). PROBLEM OR ISSUE ADDRESSED: Budgets for cancer treatments are rising 
steadily with the advent of newer targeted therapies, in an era of health care cost 
containment. The issues of budgetary constraints and formulary management create
pressure on maintaining an economically viable formulary. We conducted a pre-
approval and post-approval analysis of erlotinib, an oral anti-neoplastic agent, in stage 
IIIB/IV non-small cell lung cancer (NSCLC) in the outpatient and inpatient setting at 
a tertiary cancer center as part of our Formulary Management System (FMS). GOALS:
The goal of this study is to evaluate and analyze the budget impact of erlotinib in
stage IIIB/IV NSCLC at a tertiary cancer center. The objective of the Drug Use Policy 
and Pharmacoeconomic Department is to utilize current clinical indications, resource
utilization, and cost information to perform a budget impact analysis, as part of the 
economic analysis of all new drugs considered for inclusion into the institutional 
Formulary. An economic assessment (pre-analysis) was conducted at the time of for-
mulary evaluation and addition in May 2005, and a reassessment and budget impact 
re-evaluation (post-analysis) was executed 12 months after formulary approval, from 
June 2006 to May 2007. OUTCOMES ITEMS USED IN THE DECISION: The fol-
lowing data were collected: the number of patients; the dose amount; the number of 
doses; the number of cycles; the purchase cost, the charge amount; and the reimburse-
ment amount. The budget impact analysis was executed using direct pharmaceutical 
costs adjusted to January 2008 US dollars with the aid of the Producer Price Index 
(PPI) from the U.S. Bureau of Labor Statistics. IMPLEMENTATION STRATEGY:
The pre-approval model was based on the FDA approval of erlotinib as a second line 
therapy in stage IIIB/IV NSCLC. Parameters, such as median duration of treatment 
and indications, were gathered from published clinical trials and the expected number 
of patients were estimated from expert opinion of clinicians. The pre-approval analysis 
model estimated that it would cost the institution $1,484,220 to treat 347 stage IIIB/IV
NSCLC patients for 67 days with erlotinib. This data along with a monograph was
presented to the Pharmacy and Therapeutics (P&T) committee and the drug was 
approved to be added to the institutional Formulary. RESULTS: A reassessment and
budget impact (post-approval) analysis was executed 12 months after erlotinib was 
inducted into the formulary. The analysis reviewed the non-investigational use of 
erlotinib from June 2006 to May 2007. We had 306 patients that received erlotinib 
during that time. The number of patients using erlotinib in the outpatient setting was 
267 (87%), and on the inpatient side 39 (13%) patients utilized the drug. 155 patients 
(51%) received erlotinib as second or third line therapy for treatment of stage IIIB/IV 
NSCLC, which is lower than what the pre-approval model predicted. Sixty patients 
(20%) were on erlotinib as ﬁ rst-line therapy for locally advanced, unresectable, or
metastatic pancreatic cancer, a second indication for the drug, attained after addition 
to the institutional formulary. Finally, ninety-one patients (30%) were on erlotinib for
other non-FDA approved caner indications. The overall annual budget for total erlo-
tinib usage was similar to the initial model, $1,473,085. The budget speciﬁ cally for 
NSCLC was lower at $858,904, only 58% of the predicted amount. One possible 
reason for the lower than predicted budget impact is that erlotinib is an oral agent,
which gives patients the option of obtaining the drug from an outside pharmacy closer 
to their home, rather than utilizing the institutional pharmacy. We also evaluated the 
reimbursement data for these patients, from June 2006 to May 2007, adjusting all 
values to January 2008 dollars. The reimbursement to charge ratio for NSCLC was
65%; 62% for pancreatic cancer; and 65% for the other non-FDA approved indica-
tions. Overall, the reimbursement to charge ratio for all 306 patients was 64%, which 
is favorable to our budget expectations at the institution. LESSONS LEARNED: The 
purpose of this assessment and budget impact analysis pre-and post-approval of 
the drug onto the formulary is to evaluate the budget impact of having erlotinib on
the formulary, assessing our actual utilization patterns. We were able to meet the 
reimbursement goals for the institution for all indications of erlotinib. Performing an
annual budget impact evaluation before addition of a drug to an institution’s formu-
lary, and comparing it with the annual budget impact after a sufﬁ cient time has elapsed
for penetration of product within the institution, is an essential process in determining 
